

## **Regeneron Announces Upcoming Investor Conference Presentation**

November 15, 2017

TARRYTOWN, N.Y., Nov. 15, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast a management presentation at the 29<sup>th</sup> Annual Piper Jaffray Healthcare Conference at 4:00 p.m. ET on Tuesday, November 28, 2017.

The session may be accessed through the Company's web site, <u>www.regeneron.com</u>, on the 'Events and Presentations' page. An archived version of the presentation will be available for 30 days.

## About Regeneron Pharmaceuticals, Inc.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led by physician-scientists for nearly 30 years, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and over a dozen product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, and infectious and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its unique VelociSuite<sup>®</sup> technologies, including VelocImmune<sup>®</sup> which yields optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

## **Contact Information:**

Investor Relations Corporate Communications
Manisha Narasimhan, Ph.D. Hala Mirza
914.847.5126 914.847.3422

manisha.narasimhan@regeneron.com hala.mirza@regeneron.com

View original content:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-presentation-300556248.html

SOURCE Regeneron Pharmaceuticals, Inc.

News Provided by Acquire Media